Nasal Covid vaccine can be potential game-changer

Public health experts believe that intranasal vaccines for coronavirus, administered through nose rather than muscles, can be a potential gamechanger in Indias fight against the coronavirus pandemic.

The nasal vaccine is different from two intramuscular vaccines which recently got approval, as it is non-invasive, needle-free, doesn’t require trained healthcare workers, eliminates needle-associated risks, suits children and adults and has scalable manufacturing.
Several studies have proved that the clinical efficacy of intranasal vaccine is superior to that of injectable vaccine.

Last month, Pune-based Serum Insititute of India and Codagenix Inc had announced that they have received regulatory approval in the United Kingdom to begin an early-stage trial of their single-dose, intranasal coronavirus vaccine.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

UK asks for volunteers to be exposed to COVID-19 for research

The British government announced Wednesday that a human challenge study, which will see healthy young volunteers deliberated infected with the coronavirus, has been approved by an ethics committee. Now, researchers are calling for volunteers, as the trials are slated

Open Orphan Plc

Take a peak inside the inner workings of Open Orphan clinics

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Open Orphan’s new quarantine clinic in London

Dublin-listed Open Orphan has opened a new quarantine clinic in London. The new site is based in Whitechapel, directly opposite the Queen Mary BioEnterprise Innovation Centre (QMB) which is home to Hivivo’s – a subsidiary of Open Orphan

Open Orphan Plc

Open Orphan’s hVIVO opens a new quarantine clinic in East London

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, part of Open Orphan plc, has opened